Neuroprotective Effects of Liraglutide for Stroke Model of Rats
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The number of diabetes mellitus (DM) patients is increasing, and stroke is deeply associated with DM. Recently, neuroprotective effects of glucagon-like peptide-1 (GLP-1) are reported. In this study, we explored whether liraglutide, a GLP-1 analogue exerts therapeutic effects on a rat stroke model. Wistar rats received occlusion of the middle cerebral artery for 90 min. At one hour after reperfusion, liraglutide or saline was administered intraperitoneally. Modified Bederson’s test was performed at 1 and 24 h and, subsequently, rats were euthanized for histological investigation. Peripheral blood was obtained for measurement of blood glucose level and evaluation of oxidative stress. Brain tissues were collected to evaluate the level of vascular endothelial growth factor (VEGF). The behavioral scores of liraglutide-treated rats were significantly better than those of control rats. Infarct volumes of liraglutide-treated rats at were reduced, compared with those of control rats. The level of derivatives of reactive oxygen metabolite was lower in liraglutide-treated rats. VEGF level of liraglutide-treated rats in the cortex, but not in the striatum significantly increased, compared to that of control rats. In conclusion, this is the first study to demonstrate neuroprotective effects of liraglutide on cerebral ischemia through anti-oxidative effects and VEGF upregulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Sato et al. [66] demonstrated upregulation of VEGF in the cerebral cortex of liraglutide-treated rats subjected to MCAO; however, this was not seen within the striatum [66].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681 · cited 1×
“table; grade 2: decreased resistance to lateral push (and forelimb flexion) without circling; grade 3: same behavior as grade 2, with circling [28,29].”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · cited 3×
“Moreover, anti-inflammatory effects of liraglutide might have also influenced the results of this study, as shown in previous Alzheimer’s disease research [10].”
BackgroundResultLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“disease mouse model, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which might also suggest that therapeutic effects of exenatide were strongly related to anti-oxidative effects [8].”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“Furthermore, lixisenatide, a newly developed GLP-1 analogue exerted stronger neurogeneic effects than liraglutide on Alzheimer’s disease rodent model, although both agents breached the blood brain barrier and were bioavailable in the brain with subsequent neurogeneic effects [20].”
BackgroundHamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · cited 1×
“In several studies, neurogeneic effects of liraglutide were shown, in that the administration of liraglutide, as well as exenatide, resulted in enhanced proliferation of progenitor cells with a subsequent increase in young neurons in the dentate gyrus of high-fat-diet-fed mice [18] and Alzheimer’s disease mouse model…”
BackgroundBorlongan, C. V., Kaneko, Y., Maki, M., Yu, S.-J., Ali, M., Allickson, J. G., Sanberg, C. D., Kuzmin-Nichols, N., & Sanberg, P. R. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0340 · Cited by 205 · cited 1×
“Further studies are needed to explore the expression of other neurotrophic factors to fully recognize the therapeutic potential of liraglutide, in view of accumulating evidence that neurohumoral factors secreted from various cells are key to the neuroprotective and neurorestorative effects of cell-based therapies for…”
BackgroundSelf-citationTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201 · cited 1×
“Several reports demonstrated therapeutic effects of GLP-1 analogue on animal models of diseases in the central nervous system, including stroke, Parkinson’s disease and Alzheimer’s disease, and amyotrophic lateral sclerosis [4–8].”
BackgroundMcClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193 · cited 1×
“The same group revealed that administration of liraglutide enhances long term potentiation and suppressed the deterioration of long term potentiation in Alzheimer’s disease rat model [11].”
BackgroundPotential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · cited 1×
“Recently, neuroprotective effects of exenatide, which has 52% homologous amino-acid sequence to GLP-1, were reported in several studies [1,3].”
Result
Cited by
Items 101–119 of 119
Of mice and men: incretin actions in the central nervous system
Farr, O. M., Pilitsi, E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.013 · Cited by 3
Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model
Симаненкова, А. В., Станиславовна, Ф. О., Тимкина, Н. В., Александровна, Т. П., Vlasov, T. D., & Каронова, Т. Л. (2023) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2023-29-6-579-592 · Cited by 3
Zhang, Y., Kang, Z., Wang, J., Liu, S., Liu, X., Li, Z., Li, Y., Wang, Y., Fu, Z., Li, J., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117487 · Cited by 3
Симаненкова, А. В., Макарова, М. Н., Васильевна, В. Л., Butomo, M. I., Владимировна, Д. С., & Shlyakhto, E. V. (2018) · Regional blood circulation and microcirculation · doi:10.24884/1682-6655-2018-17-2-57-63 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Prá, M. D., Ferreira, G. K., de Mello, A. H., Schraiber, R. D. B., Cardoso, L. C., Souza, L. D. R., da Rosa, N., Fortunato, J. J., & Rezin, G. T. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0016 · Cited by 2
Wu, D., Xu, D., Fan, Y., Xu, N., Yao, T., & Liao, M. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01646-x · Cited by 2
“In addition, it was reported that liraglutide, a new type of antidiabetic treatment, had the properties of cerebrovascular protection, which might contribute to stroke prevention [31, 32].”
BackgroundSawamura, T., Karashima, S., Ohmori, A., Sawada, K. B., Kometani, M., Takeda, Y., & Yoneda, T. (2022) · Medicina · doi:10.3390/medicina58020289 · Cited by 2
“reported that liraglutide, one of GLP-1 analogues, increases VEGF level in brain tissue and decreases infarct volume in rats that received middle cerebral artery occlusion [10].”
BackgroundNew therapeutic hypothesis for infantile extrinsic hydrocephalus
Kameda, M., Kajimoto, Y., & Wanibuchi, M. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1215560 · Cited by 1
Self-citationEffect of GLP-1R Knockout on stroke outcome
Voinea, A. (2014) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Fernandes, L. S. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2017.tde-03072017-074355 · Cited by 1
Neuroprotective Therapies for Ischemic Stroke
Cruz, Y., Saldaña, K. A. C., & Ibarra, A. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012539-00064
The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases
Verdile, G., Fraser, P. E., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch4
Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico
Costanzo, G., & Frasca, F. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01064-x
“Gli effetti neuroprotettivi dei GLP1RAs potrebbero inoltre ridurre i danni correlati ai fenomeni ischemici nei pazienti con episodi di stroke [28, 29].”
BackgroundAVC, nouveaux traitements : place des agonistes du récepteur du GLP-1
Vergès, B. L. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.07.005
Sasidharan, S., & Lahareesh, B. L. (2025) · Global Journal of Health Sciences and Research · doi:10.25259/gjhsr_19_2025
Yabuno, S., Yasuhara, T., Nagase, T., Kawauchi, S., Sugahara, C., Okazaki, Y., Hosomoto, K., Sasada, S., Sasaki, T., Tajiri, N., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26563663
Self-citationCandeias, E. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
GLP-1 agonist and neuroprotection in Stroke and Parkinson’s disease: A systematic review
Parekh, D. S., Kudaiarov, D., Inban, P., Agrawal, A., Prajjwal, P., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102151
Metadata
- Authors
- Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., Sasaki, T., Sasada, S., Kondo, A., Borlongan, C., Matsumae, M., & Date, I.
- Affiliations
- Tokai University (JP)
- Okayama University (JP)
- University of Kochi (JP)
- Department of Neurosurgery, University of South Florida College Medicine, Tampa, FL 12901, USA
- Corresponding author
- Yasuhara, Takao
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2013-10-30
- Volume
- 14
- Issue
- 11
- Pages
- 21513-21524
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3856019
- OpenAlex
- W2094706071
- Cited by
- 120
- References
- 30
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 10 · 2021: 6 · 2020: 11 · 2019: 13 · 2018: 18 · 2017: 10 · 2016: 10 · 2015: 17 · 2014: 4
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (23791602, 23390349)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, neuroprotection, stroke, cerebral ischemia, middle cerebral artery occlusion, GLP-1 analogues, oxidative stress, reactive oxygen species, vascular endothelial growth factor, infarct size, diabetes mellitus, reperfusion
- MeSH terms
- Liraglutide, Animals, Blood Glucose, Disease Models, Animal, Humans, Oxidative Stress, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Stroke, Vascular Endothelial Growth Factor A, Diabetes Complications, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.